[go: up one dir, main page]

BR9811298A - Uso de um composto de vanádio fisiologicamente aceitável - Google Patents

Uso de um composto de vanádio fisiologicamente aceitável

Info

Publication number
BR9811298A
BR9811298A BR9811298-8A BR9811298A BR9811298A BR 9811298 A BR9811298 A BR 9811298A BR 9811298 A BR9811298 A BR 9811298A BR 9811298 A BR9811298 A BR 9811298A
Authority
BR
Brazil
Prior art keywords
physiologically acceptable
vanadium compound
acceptable vanadium
surrounding tissue
injury
Prior art date
Application number
BR9811298-8A
Other languages
English (en)
Inventor
Conradus Ghosal Gho
Original Assignee
Gho St Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gho St Holding Bv filed Critical Gho St Holding Bv
Publication of BR9811298A publication Critical patent/BR9811298A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

"USO DE UM COMPOSTO DE VANáDIO FISIOLOGICAMENTE ACEITáVEL". Uso de um composto de vanádio fisiologicamente aceitável, sal ou complexo como um componente ativo na preparação de uma composição farmacêutica para o tratamento profilático de dano secundário de tecido, referido dano secundário sendo induzido por dano primário de tecido principalmente circundante, particularmente tecido circundante, e sendo o resultado de um evento traumático.
BR9811298-8A 1997-07-29 1998-07-29 Uso de um composto de vanádio fisiologicamente aceitável BR9811298A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
PCT/NL1998/000431 WO1999006056A1 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes

Publications (1)

Publication Number Publication Date
BR9811298A true BR9811298A (pt) 2000-08-29

Family

ID=19765422

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811298-8A BR9811298A (pt) 1997-07-29 1998-07-29 Uso de um composto de vanádio fisiologicamente aceitável

Country Status (22)

Country Link
US (2) US6579540B1 (pt)
EP (1) EP1001792B1 (pt)
JP (1) JP2001511454A (pt)
CN (1) CN1104244C (pt)
AT (1) ATE253373T1 (pt)
AU (1) AU738701B2 (pt)
BR (1) BR9811298A (pt)
CA (1) CA2298645C (pt)
CZ (1) CZ299716B6 (pt)
DE (1) DE69819514T2 (pt)
DK (1) DK1001792T3 (pt)
EA (1) EA002574B1 (pt)
ES (1) ES2207851T3 (pt)
ID (1) ID24870A (pt)
IL (2) IL134259A0 (pt)
NL (1) NL1006681C2 (pt)
NO (1) NO20000446L (pt)
NZ (1) NZ502613A (pt)
PL (1) PL338415A1 (pt)
PT (1) PT1001792E (pt)
TR (1) TR200000349T2 (pt)
WO (1) WO1999006056A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
AU1898700A (en) * 1999-12-20 2001-07-03 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and NA+/H+ exchange inhibitor
WO2003041703A2 (en) * 2001-11-16 2003-05-22 Gho Holding B.V. Use of a flavonoid for the treatment of burns
AU2008209677B2 (en) 2007-01-31 2013-05-23 Basf Plant Science Gmbh Plants having enhanced yield-related traits and/or increased abiotic stress resistance, and a method for making the same
CA2900183A1 (en) 2007-05-03 2008-11-13 Yves Hatzfeld Plants having enhanced yield-related traits and a method for making the same
AR067633A1 (es) 2007-07-20 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para producirlas
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
CN101842489B (zh) 2007-10-29 2012-12-26 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物和用于制备该植物的方法
AU2009243552A1 (en) 2008-05-05 2009-11-12 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
JP5878477B2 (ja) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 骨の治癒を加速するためのバナジウム化合物の使用
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
WO2013006798A1 (en) * 2011-07-06 2013-01-10 University Of Medicine And Dentistry Of New Jersey Vandium compounds as therapeutic adjuncts for cartilage regeneration and repair
BR112013014177A2 (pt) 2010-12-10 2016-07-12 Univ New Jersey Med dispositivo de implante revestido com composto e seus métodos
CA2829259C (en) * 2011-03-07 2020-02-25 Cfm Pharma Holding Bv Use of vanadium compounds for maintaining normaglycemia in a mammal
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5448490A (en) * 1989-04-24 1990-11-16 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
FR2729957B1 (fr) * 1995-01-31 1997-12-05 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant.
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Also Published As

Publication number Publication date
EA200000176A1 (ru) 2000-10-30
PT1001792E (pt) 2004-03-31
CN1270525A (zh) 2000-10-18
AU738701B2 (en) 2001-09-27
TR200000349T2 (tr) 2000-09-21
IL134259A0 (en) 2001-04-30
DE69819514T2 (de) 2004-09-23
JP2001511454A (ja) 2001-08-14
NZ502613A (en) 2001-08-31
NO20000446L (no) 2000-03-24
CZ2000326A3 (cs) 2000-07-12
ES2207851T3 (es) 2004-06-01
CA2298645A1 (en) 1999-02-11
DK1001792T3 (da) 2004-01-19
IL134259A (en) 2010-02-17
CA2298645C (en) 2004-05-18
US20030211170A1 (en) 2003-11-13
ID24870A (id) 2000-08-31
NO20000446D0 (no) 2000-01-28
EA002574B1 (ru) 2002-06-27
EP1001792B1 (en) 2003-11-05
US6579540B1 (en) 2003-06-17
CZ299716B6 (cs) 2008-10-29
WO1999006056A1 (en) 1999-02-11
EP1001792A1 (en) 2000-05-24
PL338415A1 (en) 2000-11-06
DE69819514D1 (de) 2003-12-11
ATE253373T1 (de) 2003-11-15
AU8650598A (en) 1999-02-22
NL1006681C2 (nl) 1999-02-08
CN1104244C (zh) 2003-04-02

Similar Documents

Publication Publication Date Title
BR9811298A (pt) Uso de um composto de vanádio fisiologicamente aceitável
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
PT948527E (pt) Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem
WO1995031985A3 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
DE69932510D1 (de) Vaskularisierungsinhibitoren
BR0013009A (pt) Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos
EP0934065A4 (en) PHARMACEUTICAL COMPOSITION
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
WO1998009599A3 (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
HUP0103819A3 (en) Crystalline efavirenz pharmaceutical compositions containing it as active ingredient, and use of efavirenz for making medicament available for inhibitions of reverse transcriptase and for treating hiv infection
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
CA2385755A1 (en) Prevention of colorectal cancer
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
BR0115911A (pt) Uso de pirazolo[4,3-d]pirimidinas
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]